期刊文献+

多发性骨髓瘤骨病发生机制研究进展 被引量:7

Progress in the mechanisms of multiple myeloma bone diseases
原文传递
导出
摘要 多发性骨髓瘤骨病(MMBD)是由浆细胞恶性增殖引起的一系列溶骨性改变,包括骨骼疼痛、高钙血症、骨质疏松、病理性骨折等,起病隐匿、误诊率高,预后差。其核心机制主要是破骨细胞活性增强,成骨细胞被抑制导致的骨模型稳态失衡。近期越来越多的研究认为骨细胞是调节破骨细胞和成骨细胞活性的中心,且MMBD的发生受某些因子调控。文章对MMBD的发生机制进行综述。 Multiple myeloma bone diseases (MMBD) is a series of osteolytic changes caused by plasma cells malignant proliferation,including bone pain,hypercalcemia,osteoporosis,pathological fracture,etc.MMBD has insidious onset,high misdiagnosis rate and poor prognosis.The broken-up bone homeostasis model due to the activated osteoclasts and inhibited osteoblasts is considered as the core mechanism.More and more studies suggest that osteocyte is the key to regulate the activity of osteoclasts and osteoblasts,and the occurrence of MMBD is regulated by some cytokines.This article reviews the mechanisms of MMBD.
作者 杨世伟 朱尊民 Yang Shiwei;Zhu Zunmin(Department of Hematology,Zhengzhou University People's Hospital,Hematology Institute of Henan Provincial People's Hospital,Zhengzhou 450003,China)
出处 《白血病.淋巴瘤》 CAS 2019年第3期190-192,共3页 Journal of Leukemia & Lymphoma
关键词 多发性骨髓瘤 骨髓瘤骨病 预后 Multiple myeloma Myeloma bone diseases Prognosis
  • 相关文献

参考文献2

二级参考文献23

  • 1张骏,邓宏宇,巫刚.多发性骨髓瘤患者血钙异常的临床分析[J].中华血液学杂志,2005,26(4):246-247. 被引量:20
  • 2李彩霞,吴德沛,孙爱宁,苗瞄,刘跃均,赵晔,胡小惠,孙道平.硼替佐米治疗多发性骨髓瘤的初步临床研究[J].白血病.淋巴瘤,2006,15(5):349-350. 被引量:12
  • 3Terposl E, Dimopoulos MA. Myeloma bone disease: pathophysiology and management. Ann Oncol, 2005, 16: 1223-1231. 被引量:1
  • 4Lecouvet FE, Vande Berg, BC, Michaux, Lucienne et al. StageⅢ Multiple Myeloma: Clinical and Prognostic Value of Spinal Bone Marrow MR hnaging. Radiology, 1998,209:653-660. 被引量:1
  • 5Clerc D, Fermand JP,Marlette X. Treatment of multiple myeloma. Joint Bone Spine, 2003,70 : 175-186. 被引量:1
  • 6Greipp PR,San Miguel J,Durie BG,et al. International staging system for multiple myeloma. J Clin Oncnl, 2005,23 : 3412-3420. 被引量:1
  • 7Cohen HJ, Silberman HR, Tornyos K, et al. Comparison of two long- term chemotherapy regimens, with or without agents to modify skeletal repair, in muhiple myeloma. Blood, 1984,63:639-648. 被引量:1
  • 8Coxon FP, Helfrich MH, van' t Hof R, et al. Protein prenylation is required for osteoc|ast formation, fimction and survival: inhibition by hisphnsphonates and GGTI-98. J Bone Miner Res,2000,15:1467- 1476. 被引量:1
  • 9Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronale in reducing the skeletal events in patients with advanced muhilpe myeloma. N Engl J Med, 1996,334:488-493. 被引量:1
  • 10Berenson J, Rosen LS, Hmvell A, et al. Zoledronic aeid reduces skeletal-relaled events in palients with osteolytie metastases. Cancer, 2001,91:1191-1200. 被引量:1

共引文献20

同被引文献58

引证文献7

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部